Abstract:Targeted protein degradation (TPD) is emerging as a promising therapeutic approach for cancer and other diseases, with an increasing number of programs demonstrating its efficacy in human clinical trials. One notable method for TPD is Proteolysis Targeting Chimeras (PROTACs, or heterobifunctional degraders) that selectively degrade a protein of interest (POI) through E3-ligase induced ubiquitination followed by proteasomal degradation. PROTACs utilize a warhead-linker-ligand architecture to bring the POI (bound to the warhead) and the E3 ligase (bound to the ligand) into close proximity. The resulting non-native protein-protein interactions (PPIs) formed between the POI and E3 ligase lead to the formation of a stable POI-degrader-ligase ternary complex, enhancing cooperativity for TPD. A significant challenge in PROTAC design is the time-consuming and resource-intensive screening of the degrader linkers to induce favorable non-native PPIs between POI and E3 ligase. In this work, we present a physics-based computational protocol to systematically predict non-canonical and metastable PPI interfaces between an E3 ligase and a given POI, aiding in the design of linkers to stabilize the PROTAC ternary complex and enhance degradation. In our protocol, we build the non-Markovian dynamic model using the Integrative Generalized Master Equation (IGME) method from approximately 1.5 millisecond all-atom molecular dynamics (MD) simulations of linker-less encounter complex, to systematically explore the inherent PPIs between the oncogene homologue (KRAS) protein and the von Hippel-Lindau (VHL) E3 ligase. Our IGME model successfully revealed six metastable states each containing a different PPI interface. We selected three of these metastable states containing promising PPIs for linker design. Our selection criterion included the thermodynamic and kinetic stabilities of these PPIs and the accessibility of the linker to the solvent-exposed sites on the warheads and the E3 ligand. One of our selected PPIs closely matches a recent co-crystal PPI interface structure induced by an experimentally designed PROTAC with potent degradation efficacy. We anticipate that our IGME approach has significant potential for widespread application in predicting metastable POI-ligase encounter complex interfaces that can enable subsequent rational design of novel PROTACs.

Uncovering the Kinetic Characteristics and Degradation Preference of PROTAC Systems with Advanced Theoretical Analyses

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

PROTAC-induced Protein Structural Dynamics in Targeted Protein Degradation

Importance of Three-Body Problems and Protein-Protein Interactions in Proteolysis-Targeting Chimera Modeling: Insights from Molecular Dynamics Simulations

Computation, Synthesis and NMR Investigations of PROTAC Linker Conformation, Chamaleonicity and their Impacts on the Mode of Action

A close-up shot of protein-protein docking, from experiment to theory and reverse with the PROTAC performers

Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity

Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation

Accelerated Rational PROTAC Design Via Deep Learning and Molecular Simulations

Chemistries of bifunctional PROTAC degraders

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Non-Markovian Dynamic Models Identify Non-Canonical KRAS-VHL Encounter Complex Conformations for Novel PROTAC Design

Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

An overview of PROTACs: a promising drug discovery paradigm

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Recent Advances of Degradation Technologies Based on PROTAC Mechanism

Clinical considerations for the design of PROTACs in cancer

Recent Advances in PROTACs for Drug Targeted Protein Research